Kevin Koch — - at Array BioPharma

Dr. Kevin Koch, Ph.D., is the President and CEO of Edgewise Therapeutics and a Venture Partner with OrbiMed Advisors, LLC. Dr. Koch has been active in the life science industry for 25+ years with a focus on drug discovery, translational medicine and clinical development. Dr. Koch was a Co-Founder of Array Biopharma Inc. and served as its President, Chief Scientific Officer and Director from May 1998 to November 2013. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in the multiple therapeutic areas. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Prior to in Array, Dr. Koch served as an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to April 1998 for Amgen Inc. From September 1988 until May 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator-Project Coordinator for the Cellular Migration and Immunology Project Teams. Dr. Koch was formerly the Senior Vice President of Drug Discovery: Chemical and Molecular Therapeutics at Biogen, where he managed global drug discovery and biomarker development as well as the immunology and hematology teams. Dr. Koch is the Treasurer and Board Member of the Inflammation Research Association. Dr. Koch has been Director of miRagen Therapeutics, Inc. since July 2016. He is a Founding Board Member of Skyhawk Therapeutics, Inc. Dr. Koch currently serves on the boards of Neurogastrx, Inc. and Encycle Therapeutics and consults with several life science companies. Dr. Koch served as a Director of Array Biopharma, Inc. from May 1998 to October 24, 2012. He is a co-author or inventor of multiple patents and publications. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Synthetic Organic Chemistry from University of Rochester.